Zeinab Dirany, Rima El Dirany, Gustavo González Gaitano and Paul Nguewa from Universidad Pública de Navarra published a useful compilation on the therapeutic applications of cyclodextrin against Trypanosomiases and Leishmaniasis. These are certainly new research areas for CDs worth deeper exploration in the future.
This is a really creative study presented by the University of Pécs – John-Lewis Zinia Zaukuu, PhD, Lajos Szente,, Miklós Poór, et al., who examined the effects of insoluble β-CD bead polymer (BBP) on the quality of red and white wines – evaluated the BBP-induced changes in the color, the total polyphenol content as well as in the trans-resveratrol and quercetin concentrations of wine samples. Furthermore, e-tongue analyses were also performed as a highly sensitive tool to examine the influence of BBP on the taste of wines.
Cyclodextrin-based nanoparticles as drug delivery systems for gene therapy against untreatable Wolfram syndrome.
Hani Al-Salami, Abigail Pfaff, Sulev Koks (Murdoch University)
Comprehensive summary from Gabriel Rabinovich Karina V. Marino Alejandro Cagnoni Diego Croci Russo (University of Buenos Aires) on the array of galectin-targeted strategies, including small-molecule carbohydrate inhibitors, natural polysaccharides and their derivatives, peptides, peptidomimetics, and biological agents reviewing the results of clinical trials that aim to evaluate the efficacy of galectin inhibitors in patients with idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, and cancer.
See the full article on nature.com.
CDs are often used in antibacterial formulations. This review provides great insight into the variety of these products, marketed drugs, and the patent landscape. Enjoy!
Universidade Federal de Sergipe – UFS
Interesting conceptual comparison of Conventional and Mechanochemical Syntheses of Cyclodextrin Derivatives by László Jicsinszky, Giancarlo Cravotto, et al. from the University of Turin.
See the full article in Molecules.
Check out the most recent paper of our collaborators in the GENEGUT Horizon Europe consortia presenting cyclodextrin-based nanoparticles for delivery of antisense oligonucleotides targeting huntingtin. Even if we were not part of this story, we are proud to get involved in the next chapter!
University College Cork – Monique Culturato Padilha Mendonça, PhD, Caitriona O’Driscoll et al
APC Microbiome Ireland – John Cryan
This is a long-awaited approval of the very first SBECD-enabled reproxalap ophthalmic formulation delivered by Aldeyra Therapeutics to treat dry eye disease.
Reproxalap, an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications.
Dry eye disease is a common inflammatory disease estimated to affect 39 million or more adults in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished quality of life, and in severe cases, permanent vision impairment. Among many physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate and often requires weeks or months to demonstrate activity. In patients with dry eye disease, RASP may contribute to ocular inflammation, diminished tear production, ocular redness, and changes in tear lipid composition. By diminishing RASP levels, Aldeyra’s lead RASP modulator reproxalap represents a novel and differentiated approach for treating the symptoms and signs of dry eye disease.
See the full press release here
Fantastic article on the evolution of micro and nanotechnologies from Rebeca Stiepel, Eliza Duggan, Cole J. Batty, Kristy Ainslie (University of North Carolina at Chapel Hill). How far we have come already! And what could be the road ahead?
A fascinating invention from Nanjing University of Information Science and Technology about novel #anticoagulant and antithrombotic drugs – sulfate gluco-galacto-oligosaccharides.
What do you think about research in this field? If you want to vote, please follow this link!